Pilot study of 5 Azacitidine in the treatment of MDS/AML with high risk (chromosome 7 and/or complex cytogenetic abnormality) - Azacitidine for MDS with high risk cytogenetics

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003732-22-GB

Enrollment

Registered

2005-09-05

Start date

2005-10-03

Completion date

Unknown

Last updated

2019-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelodysplastic syndromes/relapsed Acute myeloid leukaemia

Interventions

Trade Name: Vidaza Product Name: Azacitidine Product Code: Azacitidine Pharmaceutical Form: Powder for injection* INN or Proposed INN: A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chromosome 7 or complex cytogenetic abnormality in MDS/AML Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Allergy to drug

Design outcomes

Primary

Measure	Time frame
Main Objective: Assess complete/cytogenetic remission in patients with chromosome 7 abnormalities ;Secondary Objective: Assess duration of response;Primary end point(s): Complete remission	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026